Dr. Todd Hembrough
Translational Medicine Advisor
Dr. Todd Hembrough, Translational Medicine Advisor, is a seasoned, entrepreneurial executive with broad expertise in cancer biology, translational medicine, drug and diagnostic development and clinical proteomics.
Most recently, Dr. Hembrough was the Vice President, Translational Medicine at AstraZeneca, where he was responsible for defining strategy and leading biomarker driven drug development efforts for ~75 immuno-oncology, antibody drug conjugate and cellular therapy drug development programs from discovery to early/late development and post-marketing. Previously, he was the President of Proteomics for NantOmics where he oversaw R&D, operations and the clinical proteomics laboratory. Prior to NantOmics, he held roles of increasing responsibility at OncoPlex Diagnostics and Expression Pathology, culminating in holding the Chief Scientific Officer and Head of R&D. In this position, Dr. Hembrough was responsible for leading the development, clinical validation and commercial launch of the first quantitative proteomic assays performed on FFPE tissue. Earlier, he was a member and leader of the Translational Oncology team at EntreMed, focusing on defining druggable molecular pathways in oncology, and inventing new drugs to target these pathways.
Dr. Hembrough obtained his Ph.D. in Biochemistry from the University of Virginia studying the role of proteinases in tumor growth and invasion. Dr. Hembrough has more than fifty publications and over sixty patents either issued or pending for technologies he has developed.
